AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11477907 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 82
Study 7867683 — intervention group
Group type: COMPARATOR
Intervention: benazepril (10 mg) + amlodipine (5 mg)
Number of subjects: 12
Study 7867683 — intervention group
Group type: EXPERIMENTAL
Intervention: benazepril (10 mg)
Number of subjects: 12
Study 7867683 — intervention group
Group type: COMPARATOR
Intervention: benazeprilat (after benazepril + amlodipine)
Number of subjects: 12
Study 7867683 — intervention group
Group type: EXPERIMENTAL
Intervention: benazeprilat (after benazepril)
Number of subjects: 12
Study 7867683 — intervention group
Group type: COMPARATOR
Intervention: amlodipine (5 mg) + benazepril (10 mg)
Number of subjects: 12
Study 7867683 — intervention group
Group type: EXPERIMENTAL
Intervention: amlodipine (5 mg)
Number of subjects: 12
Study 2464919 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiarrhythmic drugs (encainide, flecainide, moricizine, imipramine)
Number of subjects: 502
Study 2464919 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 502
Study 2464919 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 502
Study 2092 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol 20 mg t.i.d.
Number of subjects: 18
Study 2092 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 11598040 — intervention group
Group type: EXPERIMENTAL
Intervention: GBS type III CPS‐tetanus toxoid (III‐TT) conjugate vaccine with alum (12.5 microg dose)
Number of subjects: 51
Study 11598040 — intervention group
Group type: COMPARATOR
Intervention: GBS type III CPS‐tetanus toxoid (III‐TT) conjugate vaccine without alum (12.5 microg dose)
Number of subjects: 51
Study 11598040 — intervention group
Group type: EXPERIMENTAL
Intervention: Second dose of GBS III‐TT conjugate vaccine (12.5 microg dose) administered 21 months after the first dose
Number of subjects: 51
Study 11598040 — intervention group
Group type: EXPERIMENTAL
Intervention: Second dose of GBS III‐TT conjugate vaccine (12.5 microg dose) for participants with undetectable III CPS‐specific IgG before the first dose
Number of subjects: 51
Study 31793602 — intervention group
Group type: EXPERIMENTAL
Intervention: Drink containing 14 wt% digestible CHO, 0.2 wt% HM-pectin/alginate, 0.06 wt% sodium chloride
Number of subjects: 0
Study 31793602 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 29549516 — intervention group
Group type: EXPERIMENTAL
Intervention: Memantine 20 mg daily
Number of subjects: 33
Study 29549516 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 27036920 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed-suction drain
Number of subjects: 83
Study 27036920 — intervention group
Group type: COMPARATOR
Intervention: No closed-suction drain
Number of subjects: 83
Study 24552609 — intervention group
Group type: EXPERIMENTAL
Intervention: Touch-screen mode of administration
Number of subjects: 99
Study 24552609 — intervention group
Group type: COMPARATOR
Intervention: Paper-and-pencil mode of administration
Number of subjects: 99
Study 22143612 — intervention group
Group type: EXPERIMENTAL
Intervention: DTR-preserved patients
Number of subjects: 213
Study 20210911 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based cognitive therapy (MBCT)
Number of subjects: 26
Study 20210911 — intervention group
Group type: COMPARATOR
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 26
Study 20210911 — intervention group
Group type: EXPERIMENTAL
Intervention: Both MBCT and CBT
Number of subjects: 26
Study 17562672 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin
Number of subjects: 20479
Study 17562672 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated Heparin (UFH)
Number of subjects: 20479
Study 16330736 — intervention group
Group type: EXPERIMENTAL
Intervention: Bed-wetting
Number of subjects: 1666
Study 12497978 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinine (Group 1a)
Number of subjects: 14
Study 12497978 — intervention group
Group type: EXPERIMENTAL
Intervention: Artesunate (Group 1b)
Number of subjects: 14
Study 12497978 — intervention group
Group type: EXPERIMENTAL
Intervention: Artesunate (Group 2)
Number of subjects: 14
Study 12497978 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe cases (Groups 1a and 1b)
Number of subjects: 14
Study 9866361 — intervention group
Group type: EXPERIMENTAL
Intervention: Portable capillary whole blood coagulation monitor
Number of subjects: 0
Study 9866361 — intervention group
Group type: COMPARATOR
Intervention: Venipuncture/laboratory method
Number of subjects: 0
Study 7649579 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril (2 or 4 mg/d)
Number of subjects: 10
Study 7649579 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine (5 mg/d)
Number of subjects: 10
Study 7649579 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril
Number of subjects: 10
Study 7649579 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 10
Study 7649579 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril and Amlodipine
Number of subjects: 10
Study 7649579 — intervention group
Group type: COMPARATOR
Intervention: All treatments together
Number of subjects: 10
Study 2764234 — intervention group
Group type: EXPERIMENTAL
Intervention: Clindamycin
Number of subjects: 40
Study 2764234 — intervention group
Group type: COMPARATOR
Intervention: Penicillin
Number of subjects: 40
Study 180619 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatic dearterialization
Number of subjects: 406
Study 180619 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatic arterial infusion of 5-fluorouracil
Number of subjects: 406
Study 180619 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatic arterial ligation and portal venous infusion of 5-fluorouracil
Number of subjects: 406
Study 180619 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Number of subjects: 406
Study 180619 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 406
Study 30701387 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic sleeve gastrectomy (LSG)
Number of subjects: 0
Study 30701387 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 0
Study 29189032 — intervention group
Group type: EXPERIMENTAL
Intervention: Network analysis of depression and PTSD symptoms
Number of subjects: 296
Study 29189032 — intervention group
Group type: EXPERIMENTAL
Intervention: Network comparisons across risk groups
Number of subjects: 296
Study 25368978 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher protein (HP) infant formula (2.05 g per 100 mL)
Number of subjects: 691
Study 25368978 — intervention group
Group type: COMPARATOR
Intervention: Lower protein (LP) infant formula (1.25 g per 100 mL)
Number of subjects: 691
Study 25368978 — intervention group
Group type: COMPARATOR
Intervention: Breast-fed
Number of subjects: 691
Study 23696612 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivabradine
Number of subjects: 6505
Study 23696612 — intervention group
Group type: COMPARATOR
Intervention: LBBB
Number of subjects: 6505
Study 21425620 — intervention group
Group type: EXPERIMENTAL
Intervention: Low power laser (LPL) treatment, frequency of 73 Hz, 10 minutes per treatment, total dose 15 J.
Number of subjects: 70
Study 21425620 — intervention group
Group type: EXPERIMENTAL
Intervention: Low power laser (LPL) treatment.
Number of subjects: 70
Study 21425620 — intervention group
Group type: COMPARATOR
Intervention: Conservative methods of physical medicine (electrotherapy: diadynamic currents, interferent currents, electrophoresis with novocaine).
Number of subjects: 70
Study 21425620 — intervention group
Group type: COMPARATOR
Intervention: Conservative methods of physical medicine.
Number of subjects: 70
Study 19485585 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent management training
Number of subjects: 445
Study 19485585 — intervention group
Group type: EXPERIMENTAL
Intervention: Attendance in parent management training
Number of subjects: 445
Study 16928838 — intervention group
Group type: EXPERIMENTAL
Intervention: Tdap vaccine (Sanofi Pasteur - Adacel and GlaxoSmithKline - Boostrix)
Number of subjects: 229
Study 12605039 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic linoleic acid (LA) 28.5 mg and gamma-linolenic acid (GLA) 15 mg twice daily for 45 days
Number of subjects: 26
Study 12605039 — intervention group
Group type: COMPARATOR
Intervention: Control group received a tear substitute and a placebo tablet for 45 days
Number of subjects: 26
Study 11185632 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen 1 g + telmisartan 120 mg
Number of subjects: 12
Study 11185632 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen 400 mg three times daily + telmisartan 120 mg
Number of subjects: 12
Study 11185632 — intervention group
Group type: COMPARATOR
Intervention: Acetaminophen 1 g
Number of subjects: 12
Study 11185632 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen 400 mg three times daily
Number of subjects: 12
Study 8570137 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy (Ctx) and/or radiotherapy (Rtx)
Number of subjects: 81
Study 8570137 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 81
Study 1322385 — intervention group
Group type: EXPERIMENTAL
Intervention: Benign breast disease (aggregate)
Number of subjects: 0
Study 1322385 — intervention group
Group type: EXPERIMENTAL
Intervention: Proliferative benign breast disease
Number of subjects: 0
Study 1322385 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-proliferative benign breast disease
Number of subjects: 0
Study 1322385 — intervention group
Group type: EXPERIMENTAL
Intervention: Lobular carcinoma in situ and ductal carcinoma in situ
Number of subjects: 0
Study 1322385 — intervention group
Group type: EXPERIMENTAL
Intervention: Mathematical models
Number of subjects: 0
Study 1322385 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast cancer prevention trials
Number of subjects: 0
Study 6496180 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicholson score for prescribing digoxin
Number of subjects: 84
Study 31972065 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine
Number of subjects: 6
Study 31972065 — intervention group
Group type: EXPERIMENTAL
Intervention: Mepivacaine
Number of subjects: 6
Study 31972065 — intervention group
Group type: EXPERIMENTAL
Intervention: Perineural anaesthesia (positive control)
Number of subjects: 6
Study 31972065 — intervention group
Group type: COMPARATOR
Intervention: Saline (negative control)
Number of subjects: 6
Study 31418143 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous intravenous Molsidomine plus intraventricular sodium nitroprusside (SNP) boluses after TCD-confirmed macrospasm.
Number of subjects: 18
Study 29439147 — intervention group
Group type: EXPERIMENTAL
Intervention: IONIS-PTP-1BRx 200 mg once weekly for 26 weeks
Number of subjects: 92
Study 29439147 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 92
Study 27587286 — intervention group
Group type: EXPERIMENTAL
Intervention: Nap condition
Number of subjects: 60
Study 27587286 — intervention group
Group type: EXPERIMENTAL
Intervention: No-nap condition
Number of subjects: 60
Study 27587286 — intervention group
Group type: COMPARATOR
Intervention: Baseline control condition
Number of subjects: 60
Study 24673467 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial removable dental prosthesis (PRDP) with precision attachments
Number of subjects: 105
Study 24673467 — intervention group
Group type: COMPARATOR
Intervention: SDA concept aiming at pre-molar occlusion
Number of subjects: 105
Study 22764294 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-γ (IFN-γ) response using Quantiferon-Leishmania assay against three Leishmania peptide antigens
Number of subjects: 352
Study 22764294 — intervention group
Group type: EXPERIMENTAL
Intervention: Leishmanin skin test (LST)
Number of subjects: 352
Study 19695841 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute Citalopram administration
Number of subjects: 20
Study 19695841 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic Citalopram administration
Number of subjects: 20
Study 19695841 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 17337504 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing
Number of subjects: 217
Study 17337504 — intervention group
Group type: COMPARATOR
Intervention: Attention control
Number of subjects: 217
Study 15762966 — intervention group
Group type: EXPERIMENTAL
Intervention: Foley catheter
Number of subjects: 100
Study 15762966 — intervention group
Group type: COMPARATOR
Intervention: PGE2 gel
Number of subjects: 100
Study 12166504 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose intravenous corticosteroids
Number of subjects: 383
Study 10514351 — intervention group
Group type: EXPERIMENTAL
Intervention: MCP plus hydrocortisone (HC) delivered via transdermal iontophoresis (IP) at a constant current of 100 microA/cm(2) for 4 hours.
Number of subjects: 7
Study 10514351 — intervention group
Group type: COMPARATOR
Intervention: MCP alone delivered via transdermal iontophoresis (IP) at a constant current of 100 microA/cm(2) for 4 hours.
Number of subjects: 7
Study 8598936 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous cytokine mobilised blood cells (BC)
Number of subjects: 69
Study 1901418 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine (100‐300 mg/d)
Number of subjects: 48
Study 1901418 — intervention group
Group type: EXPERIMENTAL
Intervention: Maprotiline (50‐150 mg/d)
Number of subjects: 48
Study 1901418 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine
Number of subjects: 48
Study 1901418 — intervention group
Group type: EXPERIMENTAL
Intervention: Maprotiline
Number of subjects: 48
Study 7167401 — intervention group
Group type: EXPERIMENTAL
Intervention: 120 ng/kg/hr ceruletide IV
Number of subjects: 24
Study 7167401 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 ng/kg/hr ceruletide IV
Number of subjects: 24
Study 7167401 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 ng/kg/hr ceruletide IV
Number of subjects: 24
Study 7167401 — intervention group
Group type: COMPARATOR
Intervention: 0.4 mg/kg/hr pentazocine IV
Number of subjects: 24
Study 7167401 — intervention group
Group type: EXPERIMENTAL
Intervention: naloxone
Number of subjects: 24
Study 30243425 — intervention group
Group type: EXPERIMENTAL
Intervention: Hatha yoga intervention (12 sessions, 90 minutes each)
Number of subjects: 73
Study 30243425 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 73
Study 28150855 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral contraceptives
Number of subjects: 70
Study 25794868 — intervention group
Group type: EXPERIMENTAL
Intervention: Nordic hamstring exercise (NHE), performed 25 sessions over 13 weeks.
Number of subjects: 579
Study 25794868 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned), regular soccer training only.
Number of subjects: 579
Study 25794868 — intervention group
Group type: COMPARATOR
Intervention: NHE intervention group vs control group.
Number of subjects: 579
Study 25794868 — intervention group
Group type: EXPERIMENTAL
Intervention: NHE intervention compliance.
Number of subjects: 579
Study 23727419 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-day-soluble gelatin sponge particles (2DS-GSPs)
Number of subjects: 73
Study 23727419 — intervention group
Group type: COMPARATOR
Intervention: Lipiodol plus insoluble gelatin sponge particles (Gelpart)
Number of subjects: 73
Study 20573679 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultra-conservative surgical approach (bilateral cystectomy)
Number of subjects: 32
Study 20573679 — intervention group
Group type: COMPARATOR
Intervention: Less conservative surgery (oophorectomy plus controlateral cystectomy)
Number of subjects: 32
Study 18407027 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride varnish applied to test teeth
Number of subjects: 15
Study 18407027 — intervention group
Group type: COMPARATOR
Intervention: Control group (no fluoride varnish)
Number of subjects: 15
Study 16637075 — intervention group
Group type: EXPERIMENTAL
Intervention: 240 mg of clover phytoestrogens daily for 2 weeks
Number of subjects: 40
Study 16637075 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 15621100 — intervention group
Group type: EXPERIMENTAL
Intervention: Brachiocephalic loop PTFE fistula (Group 1)
Number of subjects: 46
Study 15621100 — intervention group
Group type: COMPARATOR
Intervention: Brachioaxillary PTFE fistula (Group 2)
Number of subjects: 46
Study 10921536 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc sulfate supplementation (7.7 pmol, 2200 microg daily for 90 days)
Number of subjects: 20
Study 10921536 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc sulfate supplementation
Number of subjects: 20
Study 10921536 — intervention group
Group type: COMPARATOR
Intervention: Cornstarch placebo capsule
Number of subjects: 20
Study 9150334 — intervention group
Group type: EXPERIMENTAL
Intervention: Glass syringe stored in ice-water (IW)
Number of subjects: 10
Study 9150334 — intervention group
Group type: COMPARATOR
Intervention: Plastic syringe at room temperature (RT)
Number of subjects: 10
Study 9150334 — intervention group
Group type: COMPARATOR
Intervention: Glass syringe at room temperature (RT)
Number of subjects: 10
Study 9150334 — intervention group
Group type: COMPARATOR
Intervention: Plastic syringe stored in ice-water (IW)
Number of subjects: 10
Study 9150334 — intervention group
Group type: COMPARATOR
Intervention: All other methods (plastic and glass syringes)
Number of subjects: 10
Study 8265163 — intervention group
Group type: EXPERIMENTAL
Intervention: Lid-rubbing
Number of subjects: 0
Study 8265163 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-invasive tear break-up time (NITBUT) measurement after lid raising
Number of subjects: 0
Study 8265163 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluorescein application with lid raised or not raised
Number of subjects: 0
Study 8265163 — intervention group
Group type: EXPERIMENTAL
Intervention: TBUT measurement with lid raised (not in contact with cornea)
Number of subjects: 0
Study 2858215 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoldopam (100 mg)
Number of subjects: 7
Study 2858215 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 3071032 — intervention group
Group type: EXPERIMENTAL
Intervention: diclofenac 50 mg plus B vitamins (B1, B6, B12)
Number of subjects: 238
Study 3071032 — intervention group
Group type: COMPARATOR
Intervention: diclofenac 50 mg
Number of subjects: 238
Study 29895309 — intervention group
Group type: EXPERIMENTAL
Intervention: Very high intact-protein formula (VHPF) (8 g/100 kcal)
Number of subjects: 44
Study 29895309 — intervention group
Group type: COMPARATOR
Intervention: Standard high protein formula (SHPF) (5 g/100 kcal)
Number of subjects: 44
Study 27133918 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical cancer screening with overdiagnosis information
Number of subjects: 168
Study 27133918 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical cancer screening without overdiagnosis information
Number of subjects: 168
Study 27133918 — intervention group
Group type: COMPARATOR
Intervention: Non-cancer screening test
Number of subjects: 168
Study 27133918 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical cancer screening
Number of subjects: 168
Study 24361112 — intervention group
Group type: EXPERIMENTAL
Intervention: Levodopa-carbidopa intestinal gel infusion
Number of subjects: 66
Study 24361112 — intervention group
Group type: COMPARATOR
Intervention: Immediate-release oral levodopa-carbidopa
Number of subjects: 66
Study 23020995 — intervention group
Group type: EXPERIMENTAL
Intervention: Pindolol
Number of subjects: 20
Study 23020995 — intervention group
Group type: EXPERIMENTAL
Intervention: Labetalol
Number of subjects: 20
Study 20141455 — intervention group
Group type: EXPERIMENTAL
Intervention: Teaching session on nicotine addiction (two short talks added to the standard course)
Number of subjects: 322
Study 20141455 — intervention group
Group type: COMPARATOR
Intervention: Standard smoking cessation course
Number of subjects: 322
Study 19068597 — intervention group
Group type: EXPERIMENTAL
Intervention: Expansion of ulnar nerve groove and interfascicular neurolysis under microscope
Number of subjects: 22
Study 19068597 — intervention group
Group type: COMPARATOR
Intervention: Forward moving of ulnar nerve and interfascicular neurolysis under microscope
Number of subjects: 22
Study 16099632 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate 10mg once weekly for a year
Number of subjects: 46
Study 16099632 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 16099632 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate
Number of subjects: 46
Study 14648210 — intervention group
Group type: EXPERIMENTAL
Intervention: CHOP regimen (doxorubicin 50 mg/m2, cyclophosphamide 750 mg/m2, vincristine 1.4 mg/m2, prednisolone 100 mg/body)
Number of subjects: 80
Study 14648210 — intervention group
Group type: EXPERIMENTAL
Intervention: THP-COP regimen (pirarubicin 50 mg/m2, cyclophosphamide 750 mg/m2, vincristine 1.4 mg/m2, prednisolone 100 mg/body)
Number of subjects: 80
Study 14648210 — intervention group
Group type: COMPARATOR
Intervention: Both regimens
Number of subjects: 80
Study 10986304 — intervention group
Group type: EXPERIMENTAL
Intervention: Shared care system (patient- or GP-initiated hospital review)
Number of subjects: 209
Study 10986304 — intervention group
Group type: COMPARATOR
Intervention: Rheumatologist-initiated medical review (control)
Number of subjects: 209
Study 9329344 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (total dose, 10 mg/4 days)
Number of subjects: 52
Study 9329344 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 8175269 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrified drain (ED)
Number of subjects: 24
Study 8175269 — intervention group
Group type: COMPARATOR
Intervention: Conventional drain (CD)
Number of subjects: 24
Study 8175269 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 24
Study 3948478 — intervention group
Group type: EXPERIMENTAL
Intervention: High dietary carbohydrate (CHO) intake
Number of subjects: 8
Study 3948478 — intervention group
Group type: EXPERIMENTAL
Intervention: Dieting (regardless of CHO content)
Number of subjects: 8
Study 3948478 — intervention group
Group type: EXPERIMENTAL
Intervention: T3 administration (30‐80 micrograms/day)
Number of subjects: 8
Study 29745626 — intervention group
Group type: EXPERIMENTAL
Intervention: Mentally-performed deep cervical flexor exercises
Number of subjects: 16